Literature DB >> 24997549

Glucocerebrosidase mutations in Thai patients with Parkinson's disease.

Teeratorn Pulkes1, Lulin Choubtum2, Sermsiri Chitphuk2, Ammarin Thakkinstian3, Sunsanee Pongpakdee4, Kongkiat Kulkantrakorn5, Suchat Hanchaiphiboolkul6, Somsak Tiamkao7, Pairoj Boonkongchuen8.   

Abstract

BACKGROUND: GBA mutations are an important risk factor in developing Parkinson's disease (PD) worldwide. The study aimed to determine the frequency and clinical characteristics of GBA mutations in a Thai PD cohort of 480 patients and 395 control subjects.
METHODS: Direct sequencing of GBA was performed in all early-onset PD patients (EOPD: n = 108) and 100 PD patients with age at onset over 50 years (AAO > 50y-PD). The study subsequently screened all identified mutations in the remaining AAO > 50y-PD patients and all control subjects. Predictive factors associated with risk of developing PD were analyzed. Comparisons of clinical characteristics of PD patients with and without GBA mutations were also carried out.
RESULTS: Heterozygous GBA mutations were identified in 24 patients (5%) and 2 controls (0.5%). Seven identified GBA point mutations comprised p.L444P, p.N386K, p.P428S, IVS2+1G > A, IVS9+3G > C, IVS10-9_10GT > AG and c.1309delG, of which five mutations were novel. Multiple logistic regression analysis revealed that GBA mutations were more frequent in EOPD than AAO > 50y-PD groups (OR = 4.64, P < 0.022). Patients with GBA mutations had mean age at onset (43.1 ± 10.2, mean ± standard deviation) earlier than patients without GBA mutations (54.4 ± 13.9, P = 0.002). The patients with GBA mutations also had a more rapid progressive course, in which they were more likely to have higher Hoehn and Yahr staging (OR = 4.20, P = 0.006) and slightly lower means of Schwab-England ADL score [74.1 ± 17.1 vs. 81.0 ± 18.08 (OR = 0.98, 95%CI = 0.96-1.01, P = 0.162)].
CONCLUSION: GBA mutations are an important risk of PD in the Thai population. Patients having the mutations are likely to have early onset and may exhibit more rapid motor progression.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Beta-glucosidase; Early-onset Parkinson's disease; Familial Parkinson's disease; Glucocerebrosidase

Mesh:

Substances:

Year:  2014        PMID: 24997549     DOI: 10.1016/j.parkreldis.2014.06.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson's disease: mutational spectrum and clinical features.

Authors:  Jia Lun Lim; Katja Lohmann; Ai Huey Tan; Yi Wen Tay; Khairul Azmi Ibrahim; Zariah Abdul Aziz; Ahmad Shahir Mawardi; Santhi Datuk Puvanarajah; Thien Thien Lim; Irene Looi; Joshua Chin Ern Ooi; Yuen Kang Chia; Kalai Arasu Muthusamy; Peter Bauer; Arndt Rolfs; Christine Klein; Azlina Ahmad-Annuar; Shen-Yang Lim
Journal:  J Neural Transm (Vienna)       Date:  2021-11-15       Impact factor: 3.575

Review 2.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

3.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

4.  Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis.

Authors:  Yuan Zhang; Qi-Ying Sun; Yu-Wen Zhao; Li Shu; Ji-Feng Guo; Qian Xu; Xin-Xiang Yan; Bei-Sha Tang
Journal:  Parkinsons Dis       Date:  2015-09-02

5.  Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study.

Authors:  Lulin Choubtum; Pirada Witoonpanich; Suchat Hanchaiphiboolkul; Roongroj Bhidayasiri; Onanong Jitkritsadakul; Sunsanee Pongpakdee; Suppachok Wetchaphanphesat; Pairoj Boonkongchuen; Teeratorn Pulkes
Journal:  BMC Neurol       Date:  2015-09-15       Impact factor: 2.474

Review 6.  The relationship between glucocerebrosidase mutations and Parkinson disease.

Authors:  Anna Migdalska-Richards; Anthony H V Schapira
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

7.  Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis.

Authors:  Yuan Zhang; Li Shu; Qiying Sun; Xun Zhou; Hongxu Pan; Jifeng Guo; Beisha Tang
Journal:  Front Mol Neurosci       Date:  2018-02-15       Impact factor: 5.639

Review 8.  Parkinson's Disease: Biomarkers, Treatment, and Risk Factors.

Authors:  Fatemeh N Emamzadeh; Andrei Surguchov
Journal:  Front Neurosci       Date:  2018-08-30       Impact factor: 4.677

Review 9.  Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

Authors:  Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

Review 10.  A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease.

Authors:  Yuan Zhang; Li Shu; Xun Zhou; Hongxu Pan; Qian Xu; Jifeng Guo; Beisha Tang; Qiying Sun
Journal:  Parkinsons Dis       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.